Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Wordpress Themes And Plugins
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s12325-020-01397-9.

Title:
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? | Advances in Therapy
Description:
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed or refractory (r/r) disease. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CAR T-cell therapies approved by regulatory bodies for certain patients with r/r DLBCL on the basis of demonstrated treatment effects in their pivotal single-arm trials, ZUMA-1 and JULIET, respectively. In the absence of head-to-head trials, the question of whether a valid indirect treatment comparison (ITC) between axi-cel and tisa-cel could be performed using existing evidence is of interest to patients, physicians, payers, and other stakeholders. This article addresses that question by summarizing the current evidence from clinical trials and real-world studies and discussing the challenges and limitations of potential analytical approaches associated with an ITC. Two ITC approaches attempting to adjust for cross-trial heterogeneity between ZUMA-1 and JULIET, matching-adjusted indirect comparison and regression-prediction model analysis, were evaluated. After evaluating the current clinical trial data and real-world evidence, and present and prior ITC analyses of axi-cel and tisa-cel, the authors conclude that a valid comparative analysis is not currently feasible. The substantial differences (e.g., timing of leukapheresis and enrollment, use of bridging chemotherapy [90% in JULIET vs. 0% in ZUMA-1], lymphodepleting regimens) between the two trials’ designs and patient populations preclude a robust and reliable ITC. No other approaches are able to account for such differences. The current real-world data are still too immature to be used for ITCs. Thus, drawing conclusions from such ITCs should be avoided to prevent misinforming treatment choices or limiting patient access to effective treatment options. Additional data from ongoing or future real-world studies with appropriate statistical analyses are needed to provide insights into the comparative effectiveness and safety of these two treatments.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Insurance
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?


Link.springer.com relies on WORDPRESS.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Wordpress Themes and Plugins {🎨}

What WordPress theme does this site use?

It is strange but we were not able to detect any theme on the page.

What WordPress plugins does this website use?

It is strange but we were not able to detect any plugins on the page.

Keywords {🔍}

patients, article, tisacel, trials, data, juliet, car, treatment, zuma, patient, scholar, tcell, axicel, google, clinical, therapy, realworld, lymphoma, pubmed, outcomes, bridging, therapies, trial, differences, studies, bcell, itc, comparative, chemotherapy, dlbcl, large, indirect, evidence, blood, analysis, access, model, study, care, health, received, infusion, diffuse, comparison, characteristics, axicabtagene, ciloleucel, approaches, analyses, accessed,

Topics {✒️}

uk/wp-content/uploads/2018/08/population-adjustment-tsd-final-ref-rerun uk/wp-content/uploads/2018/05/rwd-dsu-report-updated-december-2016 uk/wp-content/uploads/2016/03/tsd17-dsu-observational-data-final org/newsletter/content/patient-access-medicines-growing-challenge i-report-patients-treated-car-t-cells-ebmt-registry int/selection_medicines/committees/expert/20/applications/diffuselargebcelllymphoma uk/guidance/ta319/resources/guidance-ipilimumab org/indication-data/market-access-report/ granulocyte-macrophage colony-stimulating factor gov/2020/topics-objectives/topic/access cd19 car t-cell chimeric antigen receptor car t-cell therapies anti-car immune response car t-cell therapy double/triple hit lymphoma car t-cells bind car t-cell treatment maic matching-adjusted indirect comparison car t-cell infusion b-cell lymphomas james signorovitch & eric wu anti-cd19 bispecific car t-cell treatments double/triple gene hits open-label single-arm trials autologous-hematopoietic-cell-transplantation de/downloads/92-975-2746/2018-10-31_modul4a_axicabtagen-ciloleucel relapsed/refractory large matching-adjusted indirect comparison t-cell therapies uk/guidance/ta410 t-cell therapy org/magazine/vol9_issue2/patient_access_to_necessary_and_appropriate_medical_care tisa-cel patient-level data population-adjusted indirect comparisons autologous t-cells utilizing patient-level data previously-untreated-advanced-unresectable car t-cells future real-word studies /blog/navigating-patient-access axi-cel  axicabtagene ciloleucel axi-cel axicabtagene ciloleucel current real-world timelines indirectly compare tisa-cel ich topic e10—choice future real-world studies van den neste current real-world data

Questions {❓}

  • A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
  • A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
  • Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
  • How do I report on patients treated with CAR-T cells to the EBMT Registry?
  • No head-to-head trial?
  • What was learned from this study?
  • Why carry out this study?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
         description:Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed or refractory (r/r) disease. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CAR T-cell therapies approved by regulatory bodies for certain patients with r/r DLBCL on the basis of demonstrated treatment effects in their pivotal single-arm trials, ZUMA-1 and JULIET, respectively. In the absence of head-to-head trials, the question of whether a valid indirect treatment comparison (ITC) between axi-cel and tisa-cel could be performed using existing evidence is of interest to patients, physicians, payers, and other stakeholders. This article addresses that question by summarizing the current evidence from clinical trials and real-world studies and discussing the challenges and limitations of potential analytical approaches associated with an ITC. Two ITC approaches attempting to adjust for cross-trial heterogeneity between ZUMA-1 and JULIET, matching-adjusted indirect comparison and regression-prediction model analysis, were evaluated. After evaluating the current clinical trial data and real-world evidence, and present and prior ITC analyses of axi-cel and tisa-cel, the authors conclude that a valid comparative analysis is not currently feasible. The substantial differences (e.g., timing of leukapheresis and enrollment, use of bridging chemotherapy [90% in JULIET vs. 0% in ZUMA-1], lymphodepleting regimens) between the two trials’ designs and patient populations preclude a robust and reliable ITC. No other approaches are able to account for such differences. The current real-world data are still too immature to be used for ITCs. Thus, drawing conclusions from such ITCs should be avoided to prevent misinforming treatment choices or limiting patient access to effective treatment options. Additional data from ongoing or future real-world studies with appropriate statistical analyses are needed to provide insights into the comparative effectiveness and safety of these two treatments.
         datePublished:2020-06-10T00:00:00Z
         dateModified:2020-06-10T00:00:00Z
         pageStart:3040
         pageEnd:3058
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s12325-020-01397-9
         keywords:
            Anti-CD19 chimeric antigen receptor T-cell therapies
            Axicabtagene ciloleucel
            Diffuse large B-cell lymphoma
            Indirect treatment comparison
            Tisagenlecleucel
            Internal Medicine
            Oncology
            Cardiology
            Rheumatology
            Endocrinology
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12325-020-01397-9/MediaObjects/12325_2020_1397_Fig1_HTML.png
         isPartOf:
            name:Advances in Therapy
            issn:
               1865-8652
               0741-238X
            volumeNumber:37
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jie Zhang
               affiliation:
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Junlong Li
               affiliation:
                     name:Analysis Group, Inc.
                     address:
                        name:Analysis Group, Inc., Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Qiufei Ma
               affiliation:
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hongbo Yang
               affiliation:
                     name:Analysis Group, Inc.
                     address:
                        name:Analysis Group, Inc., Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James Signorovitch
               affiliation:
                     name:Analysis Group, Inc.
                     address:
                        name:Analysis Group, Inc., Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric Wu
               affiliation:
                     name:Analysis Group, Inc.
                     address:
                        name:Analysis Group, Inc., Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
      description:Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed or refractory (r/r) disease. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CAR T-cell therapies approved by regulatory bodies for certain patients with r/r DLBCL on the basis of demonstrated treatment effects in their pivotal single-arm trials, ZUMA-1 and JULIET, respectively. In the absence of head-to-head trials, the question of whether a valid indirect treatment comparison (ITC) between axi-cel and tisa-cel could be performed using existing evidence is of interest to patients, physicians, payers, and other stakeholders. This article addresses that question by summarizing the current evidence from clinical trials and real-world studies and discussing the challenges and limitations of potential analytical approaches associated with an ITC. Two ITC approaches attempting to adjust for cross-trial heterogeneity between ZUMA-1 and JULIET, matching-adjusted indirect comparison and regression-prediction model analysis, were evaluated. After evaluating the current clinical trial data and real-world evidence, and present and prior ITC analyses of axi-cel and tisa-cel, the authors conclude that a valid comparative analysis is not currently feasible. The substantial differences (e.g., timing of leukapheresis and enrollment, use of bridging chemotherapy [90% in JULIET vs. 0% in ZUMA-1], lymphodepleting regimens) between the two trials’ designs and patient populations preclude a robust and reliable ITC. No other approaches are able to account for such differences. The current real-world data are still too immature to be used for ITCs. Thus, drawing conclusions from such ITCs should be avoided to prevent misinforming treatment choices or limiting patient access to effective treatment options. Additional data from ongoing or future real-world studies with appropriate statistical analyses are needed to provide insights into the comparative effectiveness and safety of these two treatments.
      datePublished:2020-06-10T00:00:00Z
      dateModified:2020-06-10T00:00:00Z
      pageStart:3040
      pageEnd:3058
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s12325-020-01397-9
      keywords:
         Anti-CD19 chimeric antigen receptor T-cell therapies
         Axicabtagene ciloleucel
         Diffuse large B-cell lymphoma
         Indirect treatment comparison
         Tisagenlecleucel
         Internal Medicine
         Oncology
         Cardiology
         Rheumatology
         Endocrinology
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12325-020-01397-9/MediaObjects/12325_2020_1397_Fig1_HTML.png
      isPartOf:
         name:Advances in Therapy
         issn:
            1865-8652
            0741-238X
         volumeNumber:37
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jie Zhang
            affiliation:
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Junlong Li
            affiliation:
                  name:Analysis Group, Inc.
                  address:
                     name:Analysis Group, Inc., Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Qiufei Ma
            affiliation:
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hongbo Yang
            affiliation:
                  name:Analysis Group, Inc.
                  address:
                     name:Analysis Group, Inc., Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James Signorovitch
            affiliation:
                  name:Analysis Group, Inc.
                  address:
                     name:Analysis Group, Inc., Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric Wu
            affiliation:
                  name:Analysis Group, Inc.
                  address:
                     name:Analysis Group, Inc., Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Advances in Therapy
      issn:
         1865-8652
         0741-238X
      volumeNumber:37
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:Analysis Group, Inc.
      address:
         name:Analysis Group, Inc., Boston, USA
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:Analysis Group, Inc.
      address:
         name:Analysis Group, Inc., Boston, USA
         type:PostalAddress
      name:Analysis Group, Inc.
      address:
         name:Analysis Group, Inc., Boston, USA
         type:PostalAddress
      name:Analysis Group, Inc.
      address:
         name:Analysis Group, Inc., Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jie Zhang
      affiliation:
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:Junlong Li
      affiliation:
            name:Analysis Group, Inc.
            address:
               name:Analysis Group, Inc., Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Qiufei Ma
      affiliation:
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:Hongbo Yang
      affiliation:
            name:Analysis Group, Inc.
            address:
               name:Analysis Group, Inc., Boston, USA
               type:PostalAddress
            type:Organization
      name:James Signorovitch
      affiliation:
            name:Analysis Group, Inc.
            address:
               name:Analysis Group, Inc., Boston, USA
               type:PostalAddress
            type:Organization
      name:Eric Wu
      affiliation:
            name:Analysis Group, Inc.
            address:
               name:Analysis Group, Inc., Boston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:Analysis Group, Inc., Boston, USA
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:Analysis Group, Inc., Boston, USA
      name:Analysis Group, Inc., Boston, USA
      name:Analysis Group, Inc., Boston, USA

External Links {🔗}(191)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.56s.